Obesity and autologous stem cell transplantation in acute myeloid leukemia

Obesity and autologous stem cell transplantation in acute myeloid leukemia
复制标题

DOI:
10.1038/sj.bmt.1703145
复制
发表时间:
2001-08-01
影响因子:
4.8
通讯作者:
Mandelli, F
Mandelli, F
中科院分区:
医学3区
文献类型:
--
作者:
Meloni, G;Proia, A;Mandelli, F

文献摘要

被引文献

相似文献

在骨髓移植背景下,几位作者假设严重超重的患者发生移植相关毒性的风险增加,但分析了不同的肥胖定义、不同的体重分组和异质性患者样本。为了克服这些局限性,我们回顾性地考虑了一组同质的54例患者(中位年龄36.5岁),诊断为原发性急性髓性白血病(AML),在首次完全缓解(CR)时采用Bu-Cy 2预处理方案进行自体移植,根据实际体重给药。使用体重指数(BMI = kg/m2)将患者分为三组(肥胖、非肥胖、体重不足);我们分析了每组的移植相关毒性和死亡率、总生存率和无病生存率(OS/DFS)。尽管患者数量相对较少,但在我们的研究结果中,高BMI似乎是治疗相关毒性和死亡率增加的预测因素。此外,30例(55%)患者目前仍存活于连续CR中,在中位随访76.5个月(范围14-137)后,肥胖组和非肥胖组的OS和DFS存在统计学显著差异(分别为P = 0.012和0.021)。我们的研究表明,肥胖可能是AML自体移植的一个独立危险因素,需要进一步研究。
In the bone marrow transplant setting, several authors hypothesized that severely overweight patients are at increased risk of transplant-related toxicity, but different definitions of obesity, different body weight groupings and heterogeneous samples of patients were analyzed. To overcome these limitations, we retrospectively considered a homogeneous group of 54 patients (median age 36.5 years), with a diagnosis of de novo acute myeloid leukemia (AML), autografted in first complete remission (CR) with the Bu-Cy2 conditioning regimen, dosed on actual body weight. Patients were classified into three groups (obese, non-obese, underweight) using body mass index (BMI = kg/m(2)); for each group we analyzed transplant-related toxicity and mortality, overall survival and disease-free survival (OS/DFS). In spite of the relatively small number of patients, in our results high BMI appears a predictive factor for an increase of treatment-related toxicity and mortality. Moreover, 30 (55%) patients are currently alive in continuous CR, and after a median follow-up of 76.5 months (range 14-137) statistically significant differences in OS and DFS were detected between obese and non-obese groups (P = 0.012 and 0.021, respectively). Our study sugggests that obesity may represent an independent risk factor for autograft in AML and further investigations are warranted.